Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H
Cancer Drug Resist. 2025; 8:7.
PMID: 40051496
PMC: 11883236.
DOI: 10.20517/cdr.2024.164.
Li X, Zhang W, Fang Y, Sun T, Chen J, Tian R
J Transl Med. 2025; 23(1):289.
PMID: 40050992
PMC: 11887098.
DOI: 10.1186/s12967-025-06261-4.
Mazzolini L, Touriol C
Biomolecules. 2025; 15(2).
PMID: 40001551
PMC: 11852789.
DOI: 10.3390/biom15020248.
Lordello L, Nuan-Aliman S, Kielbassa-Elkadi K, Montagne A, Kotta K, Martins I
Cancers (Basel). 2025; 17(3).
PMID: 39941763
PMC: 11816127.
DOI: 10.3390/cancers17030394.
Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A
Nat Rev Cancer. 2025; .
PMID: 39833533
DOI: 10.1038/s41568-024-00786-4.
Ovarian tumor microenvironment contributes to tumor progression and chemoresistance.
Ponton-Almodovar A, Sanderson S, Rattan R, Bernard J, Horibata S
Cancer Drug Resist. 2025; 7():53.
PMID: 39802952
PMC: 11724355.
DOI: 10.20517/cdr.2024.111.
Noncanonical UPR factor CREB3L2 drives immune evasion of triple-negative breast cancer through Hedgehog pathway modulation in T cells.
Cao Z, You J, Fan Y, Yang J, Sun J, Ma X
Sci Adv. 2025; 11(2):eads5434.
PMID: 39792663
PMC: 11721608.
DOI: 10.1126/sciadv.ads5434.
Challenges in Metabolite Biomarkers as Avenues of Diagnosis and Prognosis of Cancer.
Sharma N, Sarode S, Sekar G, Sonawane K, Bomle D
J Cancer Prev. 2025; 29(4):105-112.
PMID: 39790219
PMC: 11706722.
DOI: 10.15430/JCP.24.015.
Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") for development of targeted drug delivery and personalized therapy approaches.
Zimina T, Sitkov N, Gareev K, Mikhailova N, Combs S, Shevtsov M
Front Med (Lausanne). 2024; 11:1452298.
PMID: 39629230
PMC: 11611596.
DOI: 10.3389/fmed.2024.1452298.
Towards verifiable cancer digital twins: tissue level modeling protocol for precision medicine.
Kemkar S, Tao M, Ghosh A, Stamatakos G, Graf N, Poorey K
Front Physiol. 2024; 15:1473125.
PMID: 39507514
PMC: 11537925.
DOI: 10.3389/fphys.2024.1473125.
Site of breast cancer metastasis is independent of single nutrient levels.
Abbott K, Subudhi S, Ferreira R, Gultekin Y, Steinbuch S, Munim M
bioRxiv. 2024; .
PMID: 39484531
PMC: 11527034.
DOI: 10.1101/2024.10.24.616714.
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective.
Xiao Y, Li Y, Zhao H
Mol Cancer. 2024; 23(1):202.
PMID: 39294747
PMC: 11409752.
DOI: 10.1186/s12943-024-02113-9.
Spatial single-cell isotope tracing reveals heterogeneity of de novo fatty acid synthesis in cancer.
Buglakova E, Ekelof M, Schwaiger-Haber M, Schlicker L, Molenaar M, Shahraz M
Nat Metab. 2024; 6(9):1695-1711.
PMID: 39251875
PMC: 11422168.
DOI: 10.1038/s42255-024-01118-4.
Lymphatic system regulation of anti-cancer immunity and metastasis.
Lei P, Fraser C, Jones D, Ubellacker J, Padera T
Front Immunol. 2024; 15:1449291.
PMID: 39211044
PMC: 11357954.
DOI: 10.3389/fimmu.2024.1449291.
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.
Majumder B, Nataraj N, Maitreyi L, Datta S
Front Immunol. 2024; 15:1414376.
PMID: 39100682
PMC: 11294168.
DOI: 10.3389/fimmu.2024.1414376.
Application of the Hydrophilic Interaction Liquid Chromatography (HILIC-MS) Novel Protocol to Study the Metabolic Heterogeneity of Glioblastoma Cells.
Sofranko J, Gondas E, Murin R
Metabolites. 2024; 14(6).
PMID: 38921432
PMC: 11205371.
DOI: 10.3390/metabo14060297.
Glutathione Dynamics in the Tumor Microenvironment: A Potential Target of Cancer Stem Cells and T Cells.
Park Y, Jeong E
Int J Stem Cells. 2024; 17(3):270-283.
PMID: 38919125
PMC: 11361844.
DOI: 10.15283/ijsc24060.
Engineering Tumor Stroma Morphogenesis Using Dynamic Cell-Matrix Spheroid Assembly.
Buckenmeyer M, Brooks E, Taylor M, Yang L, Holewinski R, Meyer T
bioRxiv. 2024; .
PMID: 38903106
PMC: 11188064.
DOI: 10.1101/2024.03.19.585805.
Metabolic Signaling in Cancer Metastasis.
Krieg S, Fernandes S, Kolliopoulos C, Liu M, Fendt S
Cancer Discov. 2024; 14(6):934-952.
PMID: 38592405
PMC: 7616057.
DOI: 10.1158/2159-8290.CD-24-0174.